Biodexa Pharmaceuticals PLC
BDRX1.560USD
+0.140+9.86%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
10.43BMarktkapitalisierung
--KGV TTM
mehr Informationen über Biodexa Pharmaceuticals PLC Unternehmen
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
Unternehmensinformationen
Unternehmens-codeBDRX
Name des UnternehmensBiodexa Pharmaceuticals PLC
IPO-datumDec 08, 2014
Gegründet am2014
CEOMr. Stephen A. Stamp
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
GeschäftsjahresendeDec 08
Addresse1 Caspian Point
StadtABINGDON
BörseNASDAQ Capital Market Consolidated
LandUnited Kingdom
PostleitzahlCF10 4DQ
Telefon4401235888300
Websitehttps://www.biodexapharma.com/
Unternehmens-codeBDRX
IPO-datumDec 08, 2014
Gegründet am2014
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
--
--
Dr. Sijmen (Sijmen) De Vries, M.D.
Dr. Sijmen (Sijmen) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Controller
Group Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
--
--
Dr. Sijmen (Sijmen) De Vries, M.D.
Dr. Sijmen (Sijmen) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Controller
Group Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Umsatzaufteilung
Währung: GBPUpdate-Zeit: Sun, Apr 6
Währung: GBPUpdate-Zeit: Sun, Apr 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Keine Daten
Nach RegionGBP
Name
Umsatz
Anteil
Belgium
381.00K
100.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: Wed, Apr 16
Update-Zeit: Wed, Apr 16
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Brio Capital Management LLC
6.55%
Abbe (Richard)
0.95%
Bukwang Pharmaceutical Co., Ltd.
0.55%
Melior Pharmaceuticals I, Inc.
0.55%
Mercer Street Capital Partners, LLC
0.55%
Other
90.84%
Aktionärsstatistik
Aktionäre
Anteil
Brio Capital Management LLC
6.55%
Abbe (Richard)
0.95%
Bukwang Pharmaceutical Co., Ltd.
0.55%
Melior Pharmaceuticals I, Inc.
0.55%
Mercer Street Capital Partners, LLC
0.55%
Other
90.84%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
6.61%
Corporation
1.35%
Individual Investor
0.95%
Investment Advisor
0.84%
Venture Capital
0.21%
Hedge Fund
0.20%
Other
89.84%
Institutionelle Beteiligung
Update-Zeit: Sat, Feb 22
Update-Zeit: Sat, Feb 22
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
37
258.79K
38.71%
+145.28K
2024Q4
37
258.63K
38.68%
+145.03K
2024Q3
39
166.61K
38.54%
+138.41K
2024Q2
36
78.92K
24.69%
+69.19K
2024Q1
28
31.04K
21.44%
+27.53K
2023Q4
30
32.82K
23.15%
+31.84K
2023Q3
21
574.00
6.29%
-2.15K
2023Q2
21
425.00
5.59%
-1.99K
2023Q1
22
183.00
8.18%
-2.20K
2022Q4
21
54.00
9.96%
+24.00
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Brio Capital Management LLC
167.68K
25.08%
+110.57K
+193.59%
Nov 14, 2024
Abbe (Richard)
24.34K
3.64%
+24.34K
--
Jul 19, 2024
Bukwang Pharmaceutical Co., Ltd.
14.18K
2.12%
+14.18K
--
Apr 01, 2024
Melior Pharmaceuticals I, Inc.
14.18K
2.12%
+14.18K
--
Apr 01, 2024
Mercer Street Capital Partners, LLC
14.18K
2.12%
+7.93K
+126.83%
Apr 01, 2024
UBS Financial Services, Inc.
7.05K
1.05%
-3.17K
-31.03%
Dec 31, 2024
GS Capital Partners LLC
6.31K
0.94%
+6.31K
--
Apr 01, 2024
Ionic Ventures LLC
5.42K
0.81%
+5.33K
+5.92K%
Dec 31, 2023
District 2 Capital LP
4.03K
0.6%
-4.49K
-52.69%
Nov 11, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Datum
Art
Verhältnis
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Mar 16, 2023
Merger
4<1
Mar 16, 2023
Merger
4<1
Mehr Anzeigen